# Neoadjuvant Chemoradiation for Resectable Glioblastoma

> **NCT04209790** · PHASE2 · TERMINATED · sponsor: **Geisinger Clinic** · enrollment: 2 (actual)

## Conditions studied

- Glioblastoma
- Surgery
- High Grade Glioma

## Interventions

- **RADIATION:** Neoadjuvant chemoradiation
- **DRUG:** Drug Therapy with Temozolomide (benzolamide) (Standard of Care)
- **PROCEDURE:** Surgery post Radiation and Temozolomide (benzolamide)

## Key facts

- **NCT ID:** NCT04209790
- **Lead sponsor:** Geisinger Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-01
- **Primary completion:** 2022-09-14
- **Final completion:** 2022-09-14
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Suspended to identify a permanent PI at site level. Decision to Terminate was made on 7/29/25 because no other PI able to take on project.
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04209790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04209790, "Neoadjuvant Chemoradiation for Resectable Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04209790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*